|
gptkbp:instanceOf
|
nonsteroidal anti-inflammatory drug
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:ATCCode
|
M01AH03
|
|
gptkbp:brand
|
Bextra
|
|
gptkbp:CASNumber
|
181695-72-7
|
|
gptkbp:category
|
analgesic
anti-inflammatory agent
antipyretic
|
|
gptkbp:contraindication
|
hypersensitivity to sulfonamides
coronary artery bypass graft surgery
history of allergic-type reactions to NSAIDs
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C16H14N2O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
valdecoxib
|
|
gptkbp:IUPACName
|
4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
|
|
gptkbp:KEGGID
|
D01341
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
selective COX-2 inhibition
|
|
gptkbp:MeSH_ID
|
D000077334
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
314.36 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
2005
2087
CHEMBL122
DB00580
|
|
gptkbp:relatedTo
|
gptkb:parecoxib
|
|
gptkbp:retired
|
serious skin reactions
cardiovascular risk
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:toxic_epidermal_necrolysis
gptkb:Stevens-Johnson_syndrome
gastrointestinal discomfort
edema
hypertension
rash
|
|
gptkbp:UNII
|
3K9958V90M
|
|
gptkbp:usedFor
|
osteoarthritis
pain
rheumatoid arthritis
dysmenorrhea
|
|
gptkbp:withdrawn
|
gptkb:United_States
2005
|
|
gptkbp:bfsParent
|
gptkb:nonsteroidal_anti-inflammatory_drug
|
|
gptkbp:bfsLayer
|
6
|